EGF(A) analogues with fatty acid substituents
US10822385B2 · kind B2 · utility
1Cited by
3References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 13, 2017 |
| Grant date | Nov 3, 2020 |
| Priority date | — |
| Expiry date | Jan 13, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.